贺维斯特医药科技 HiRO

HiRO was contracted by a US-based biotech company to conduct a Phase II obesity clinical trial. The study required the recruitment of 325 eligible participants across 16 sites in Australia and New Zealand. Through the selection of quality, high-performing sites with strong recruitment track records, and meticulous planning and collaboration, we were able to support the first participant-first visit, which was achieved on the same day as the site activation. We achieved a strong recruitment performance, and after initial global targets were reviewed, the ANZ region recruitment targets were increased to 325 participants, of which 327 participants were successfully recruited in just 5 months, 2 months quicker than the estimated recruitment timelines! #ClinicalTrials #ObesityResearch #RapidStartUp #ANZRegion #HiRO

? The APAC region continues to play a critical role in the global landscape of drug development, with a strong focus on optimizing clinical trials. While smaller markets, Taiwan and Hong Kong may not be as prominent as some larger APAC countries/regions, both are making significant efforts to enhance clinical trial efficiency in order for studies to maximize the opportunities these regions present. Keep reading to see how to make the most out of the opportunities in Taiwan and Hong Kong.

Earlier this month, our team Jacquie Palmer, Elaine Gent, and Alex Baldridge, CCRA attended ObesityWeek in San Antonio, where they also had the opportunity to experience the Day of the Dead festivities! Across the pond, Sam Adamson, Ya-Han Chang, and Wenchi Lin represented us at BIO-EUROPE in Stockholm! Both teams had a great time connecting with other professionals, gaining key insights, and having the opportunity to speak on how HiRO is actively contributing to shaping the future of biotechnology. #ObesityWeek2024 #HiRO #ObesityResearch #HealthInsights #ClinicalTrials #ObesityAwareness #BIOEurope2024 #BiotechFuture #InnovationInBiotech #TeamHiRO

Join our webinar this week as we unravel the intricacies of leveraging FDA interactions to drive your projects forward. ?? ??Key Insights: ? Understand the distinct features of INTERACT, pre-IND, and Type D meetings and their unique requirements. ? Discover when and how to prepare comprehensively for successful interactions with the FDA. ? Acquire knowledge on engaging with the FDA to optimize decision-making processes in early drug development. ?? Register now to secure your spot: https://lnkd.in/dR5wMDCy Don't miss out on this opportunity to elevate your understanding of FDA interactions! #TrialWithoutBorders #HiRO #FDA #PreIND #RegulatoryWebinar

Our Silent Auction event is closing soon! We need your help! We are organizing a fundraiser for our beloved colleague and friend, Jo Holland, who many of you may know from her incredible work in clinical trials and drug research. Right now, Jo is facing a tough battle with Multiple Myeloma, and she needs our support. Jo has dedicated her career to clinical trials and drug research aimed at combating cancer, now finds herself in need of our help. Despite Jo's tireless efforts, the specific drug they require—daratumumab—is not funded in New Zealand, leaving her with limited options. This vital medication, effective in 48 countries, can provide Jo with a chance to continue her fight, but its cost exceeds $100,000 per year. If you would like to attend the fundraiser, you can purchase your tickets at https://lnkd.in/gzA5B3Qm. Your ticket grants you access to a night filled with delicious food, refreshing drinks, and the thrill of exciting quizzes, a fantastic auction, and dazzling raffles! Every dollar raised will go directly towards Jo's treatment with daratumumab, a vital medication currently unfunded in New Zealand. If you can’t attend the fundraiser, you can still bid on our silent auction on your favourite items. We are also looking for sponsorship for the fundraiser. Your organization can support by: Providing an item or services for the Silent Auction and Raffles Donations Custom Sponsorship Opportunities Feel free to contact [email protected] for further information.

China's clinical trial landscape covers a wide range of fields and study phases. As of August 2024, there have been a total 69,457 clinical trials conducted in the country - most of which are Phase I trials. 40,123 clinical trials (52.91%) are academic, and 40.55% trials are from industries. It’s getting increasingly easier for trials to access participants, achieve efficient subject enrollment and see significant cost savings due to lower patient costs in China. Keep reading to see more on key insights for China’s role in global trial development https://lnkd.in/guRsvz9Y #ChinaClinicalTrials #PhaseITrials #GlobalTrialDevelopment #ClinicalResearch

China's healthcare market is expanding rapidly due to urbanization, with a population of about 1.4 billion people. The country's aging demographic contributes to a large and diverse patient group with various diseases. With ongoing efforts being made to enhance the regulatory process, China, along with several other APAC countries, has emerged as a more streamlined and efficient hub for clinical trial activities. The country's large patient pool, coupled with its improving infrastructure, offers unique opportunities for enhanced research. Keep reading to see more on key insights for Mainland China’s role in global trial development -> https://lnkd.in/guRsvz9Y #BiotechInnovation #ClinicalDevelopment #ClinicalResearch #ClinicalTrials #DrugDevelopment #GlobalResearch

Final week to buy tickets to the fundraiser – we have reduced the price to $80 to get as many supporters as possible to attend. We also have a special guest attending the fundraiser – Dr Siouxsie Wiles, will be the master of ceremony! Your ticket grants you access to a night filled with: - Delicious food - Refreshing drinks - Exciting quizzes - A fantastic auction Click here for tickets: https://lnkd.in/g97JeiNr Jo has dedicated her career to clinical trials and drug research aimed at combating cancer, now finds herself in need of our help. Despite Jo's tireless efforts, the specific drug they require—daratumumab—is not funded in New Zealand, leaving her with limited options. This vital medication, effective in 48 countries, can provide Jo with a chance to continue her fight, but its cost exceeds $100,000 per year. We are also looking for sponsorship for the fundraiser. Your organization can support by: Providing an item or services for the Silent Auction and Raffles Donations Custom Sponsorship Opportunities Feel free to contact [email protected] for further information.

?? Explore global submissions with HiRO in this exclusive webinar! Our Regulatory Affairs and Strategy team is hosting another webinar this week, offering insights into the dynamic world of Global IND/CTA/CTN Submission. Don't miss this chance to join us! ? Insights you will gain: ?? Understand the benefits of globally synchronized R&D in reducing duplication and expediting authorization timelines. ?? Explore strategic advantages in drug development planning for enhanced distribution and reaching diverse patient populations. ?? Gain valuable insights into regulatory operations and life cycle management for multi-country clinical trials. ?? Register here to secure your spot: https://lnkd.in/dR5wMDCy #TrialsWithoutBorders #GlobalSubmission #RegulatoryStrategy #MultiCountryTrials #HiRO

According to the WHO, lung cancer is the most common cancer type and the most common cause of cancer death in the world. The most recent global estimates from the International Agency for Research on Cancer (IARC) indicate that in 2022 almost 2.5 million people were diagnosed with lung cancer and more than 1.8 million people died from the disease. Visit the IARC website to learn more about lung cancer and the research that IARC and partners are conducting to prevent more people from developing or dying from this disease. https://lnkd.in/dkd89_NW HiRO remains committed to supporting studies that are conducting groundbreaking research in an effort to find a cure. #LungCancerAwareness #CancerResearch #IARC #CancerAwarenessMonth #HiROResearch #GlobalHealth